Shares of Illumina, Inc. (NASDAQ:ILMN) have been assigned an average recommendation of “Hold” from the nineteen ratings firms that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $332.24.
ILMN has been the topic of a number of research reports. Piper Sandler dropped their target price on shares of Illumina from $370.00 to $356.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and increased their target price for the stock from $250.00 to $320.00 in a report on Friday, April 24th. They noted that the move was a valuation call. Cowen increased their target price on shares of Illumina from $275.00 to $320.00 and gave the stock an “outperform” rating in a report on Friday, May 1st. Robert W. Baird lowered shares of Illumina from an “outperform” rating to a “neutral” rating and set a $310.00 price objective on the stock. in a research report on Tuesday, April 21st. Finally, Wells Fargo & Co raised their price objective on shares of Illumina from $245.00 to $290.00 and gave the company an “underweight” rating in a research report on Friday, May 1st.
NASDAQ ILMN traded down $6.17 during trading hours on Friday, reaching $360.08. 868,230 shares of the company traded hands, compared to its average volume of 899,668. Illumina has a 12 month low of $196.78 and a 12 month high of $380.76. The company has a current ratio of 4.10, a quick ratio of 3.74 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $53.84 billion, a PE ratio of 56.71, a PEG ratio of 5.43 and a beta of 0.98. The company has a 50 day moving average of $349.26 and a two-hundred day moving average of $310.73.
In other news, CEO Francis A. Desouza sold 3,000 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $275.00, for a total transaction of $825,000.00. Following the sale, the chief executive officer now directly owns 87,158 shares of the company’s stock, valued at approximately $23,968,450. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Charles Dadswell sold 121 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $265.92, for a total value of $32,176.32. Following the sale, the senior vice president now directly owns 9,962 shares in the company, valued at $2,649,095.04. The disclosure for this sale can be found here. Insiders have sold a total of 37,128 shares of company stock worth $11,980,537 in the last quarter. Company insiders own 0.38% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ILMN. Norges Bank acquired a new stake in shares of Illumina during the 4th quarter worth $647,840,000. Loomis Sayles & Co. L P acquired a new stake in shares of Illumina during the 1st quarter worth $320,139,000. Alliancebernstein L.P. grew its holdings in shares of Illumina by 78.9% during the 4th quarter. Alliancebernstein L.P. now owns 1,881,507 shares of the life sciences company’s stock worth $624,171,000 after purchasing an additional 829,865 shares in the last quarter. Girard Partners LTD. grew its holdings in shares of Illumina by 5,762.3% during the 1st quarter. Girard Partners LTD. now owns 524,382 shares of the life sciences company’s stock worth $2,858,000 after purchasing an additional 515,437 shares in the last quarter. Finally, Sustainable Growth Advisers LP boosted its stake in Illumina by 55.7% in the first quarter. Sustainable Growth Advisers LP now owns 1,035,405 shares of the life sciences company’s stock valued at $282,790,000 after buying an additional 370,233 shares in the last quarter. 89.88% of the stock is currently owned by institutional investors.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: Short Selling Stocks and Day Traders
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.